Capecitabina Zentiva Italia (Capecitabine)

Capecitabina Zentiva Italia is indicated for the treatment of certain advanced solid tumors, primarily in the metastatic setting.

• Metastatic colorectal cancer, often in combination with other chemotherapeutic agents.
• Metastatic breast cancer, used as a single agent or with targeted therapies.
• Off‑label use in gastric or pancreatic cancer may be considered under specialist supervision.
• Adjuvant therapy for stage III colon cancer in patients who cannot receive intravenous 5‑fluorouracil.

The safety profile of capecitabine includes a range of adverse events that vary in frequency and severity.

Common

• Diarrhea or loose stools.
• Nausea and vomiting.
• Hand‑foot syndrome (palmar‑plantar erythrodysesthesia).
• Fatigue or weakness.

Serious

• Severe neutropenia or leukopenia.
• Cardiotoxicity, including chest pain or arrhythmias.
• Severe allergic reactions such as Stevens‑Johnson syndrome.

Before initiating Capecitabina Zentiva Italia, clinicians should evaluate several patient‑specific factors to minimize risk.

• Assess renal and hepatic function; dose adjustments may be required in impairment.
• Review pregnancy status; drug is contraindicated in pregnancy (Category D) and requires effective contraception.
• Monitor complete blood counts regularly for signs of myelosuppression.
• Evaluate for pre‑existing cardiac disease, as capecitabine can cause cardiotoxic effects.
• Counsel patients on recognizing hand‑foot syndrome and report early skin changes.
• Consider drug interactions, especially with anticoagulants and fluoropyrimidine‑enhancing agents.

Capecitabine may interact with other medicines, influencing its efficacy or safety.

Avoid

• Strong CYP2C9 inhibitors (e.g., fluconazole) that can increase capecitabine exposure.
• Anticoagulants such as warfarin, which may heighten bleeding risk.

Use with caution

• Antacids or proton‑pump inhibitors that alter gastric pH and affect drug absorption.
• Other fluoropyrimidines or cytotoxic agents, which can amplify myelosuppression.
• Radiation therapy to the abdomen or pelvis, increasing risk of gastrointestinal toxicity.